Skip to main content
. Author manuscript; available in PMC: 2021 Dec 1.
Published in final edited form as: Eur Urol. 2020 Aug 23;78(6):916–924. doi: 10.1016/j.eururo.2020.08.002

Table 3 ‒

Summary of treatment-emergent adverse events (TEAEs) in patients with hyperphosphatemia versus non-hyperphosphatemia

Parameter, n (%) Hyperphosphatemia (n = 48) Non-hyperphosphatemia (n = 19)
Any TEAE 48 (100.0) 18 (94.7)
Grade 3 or 4 TEAE 34 (70.8) 12 (63.2)
Serious TEAE 17 (35.4) 7 (36.8)
Treatment-related TEAE 47 (97.9) 17 (89.5)
Serious treatment-related TEAE 3 (6.3) 1 (5.3)
TEAE leading to treatment discontinuation 3 (6.3) 7 (36.8)
TEAE leading to dose interruption/dose adjustment 43 (89.6) 10 (52.6)

Hyperphosphatemia and non-hyperphosphatemia were defined as serum phosphorus levels >5.5 and ≤5.5 mg/dl after the dose, respectively.